AbbVie Statistics
Total Valuation
AbbVie has a market cap or net worth of $514.92 billion. The enterprise value is $585.47 billion.
| Market Cap | 514.92B |
| Enterprise Value | 585.47B |
Important Dates
The last earnings date was Friday, October 30, 2026, before market open.
| Earnings Date | Oct 30, 2026 |
| Ex-Dividend Date | Jan 15, 2027 |
Share Statistics
AbbVie has 1.77 billion shares outstanding.
| Current Share Class | 1.77B |
| Shares Outstanding | 1.77B |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.06% |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | 76.74% |
| Float | 1.76B |
Valuation Ratios
The trailing PE ratio is 50.16 and the forward PE ratio is 18.51. AbbVie's PEG ratio is 1.36.
| PE Ratio | 50.16 |
| Forward PE | 18.51 |
| PS Ratio | 7.80 |
| Forward PS | 7.10 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 27.29 |
| P/OCF Ratio | 25.63 |
| PEG Ratio | 1.36 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 18.38, with an EV/FCF ratio of 31.02.
| EV / Earnings | 56.82 |
| EV / Sales | 8.87 |
| EV / EBITDA | 18.38 |
| EV / EBIT | 24.21 |
| EV / FCF | 31.02 |
Financial Position
The company has a current ratio of 0.87
| Current Ratio | 0.87 |
| Quick Ratio | 0.56 |
| Debt / Equity | n/a |
| Debt / EBITDA | 2.52 |
| Debt / FCF | 4.31 |
| Interest Coverage | 8.12 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | 10.74% |
| Return on Invested Capital (ROIC) | 19.72% |
| Return on Capital Employed (ROCE) | 23.13% |
| Weighted Average Cost of Capital (WACC) | 4.99% |
| Revenue Per Employee | $1.16M |
| Profits Per Employee | $180,754 |
| Employee Count | 57,000 |
| Asset Turnover | 0.47 |
| Inventory Turnover | 3.39 |
Taxes
In the past 12 months, AbbVie has paid $2.47 billion in taxes.
| Income Tax | 2.47B |
| Effective Tax Rate | 19.24% |
Stock Price Statistics
The stock price has increased by +34.39% in the last 52 weeks. The beta is 0.19, so AbbVie's price volatility has been lower than the market average.
| Beta (5Y) | 0.19 |
| 52-Week Price Change | +34.39% |
| 50-Day Moving Average | 271.95 |
| 200-Day Moving Average | 238.95 |
| Relative Strength Index (RSI) | 59.69 |
| Average Volume (20 Days) | 5,613,329 |
Short Selling Information
The latest short interest is 15.58 million, so 0.88% of the outstanding shares have been sold short.
| Short Interest | 15.58M |
| Short Previous Month | 19.49M |
| Short % of Shares Out | 0.88% |
| Short % of Float | 0.88% |
| Short Ratio (days to cover) | 3.22 |
Income Statement
In the last 12 months, AbbVie had revenue of $66.01 billion and earned $10.30 billion in profits. Earnings per share was $5.81.
| Revenue | 66.01B |
| Gross Profit | 48.67B |
| Operating Income | 24.18B |
| Pretax Income | 12.81B |
| Net Income | 10.30B |
| EBITDA | 31.85B |
| EBIT | 24.18B |
| Earnings Per Share (EPS) | $5.81 |
Balance Sheet
The company has $10.77 billion in cash and $81.32 billion in debt, with a net cash position of -$70.54 billion or -$39.91 per share.
| Cash & Cash Equivalents | 10.77B |
| Total Debt | 81.32B |
| Net Cash | -70.54B |
| Net Cash Per Share | -$39.91 |
| Equity (Book Value) | -4.54B |
| Book Value Per Share | -2.59 |
| Working Capital | -5.62B |
Cash Flow
In the last 12 months, operating cash flow was $20.09 billion and capital expenditures -$1.22 billion, giving a free cash flow of $18.87 billion.
| Operating Cash Flow | 20.09B |
| Capital Expenditures | -1.22B |
| Depreciation & Amortization | 7.67B |
| Net Borrowing | 12.18B |
| Free Cash Flow | 18.87B |
| FCF Per Share | $10.68 |
Margins
Gross margin is 73.72%, with operating and profit margins of 36.63% and 15.67%.
| Gross Margin | 73.72% |
| Operating Margin | 36.63% |
| Pretax Margin | 19.41% |
| Profit Margin | 15.67% |
| EBITDA Margin | 48.25% |
| EBIT Margin | 36.63% |
| FCF Margin | 28.59% |
Dividends & Yields
This stock pays an annual dividend of $7.28, which amounts to a dividend yield of 2.50%.
| Dividend Per Share | $7.28 |
| Dividend Yield | 2.50% |
| Dividend Growth (YoY) | 5.41% |
| Years of Dividend Growth | 54 |
| Payout Ratio | 125.34% |
| FCF Payout Ratio | 68.19% |
| Buyback Yield | n/a |
| Shareholder Yield | 2.50% |
| Earnings Yield | 1.99% |
| FCF Yield | 3.67% |
Analyst Forecast
The average price target for AbbVie is $310.65, which is 6.64% higher than the current price. The consensus rating is "Buy".
| Price Target | $310.65 |
| Price Target Difference | 6.64% |
| Analyst Consensus | Buy |
| Analyst Count | 29 |
| Revenue Growth Forecast (3Y) | 9.27% |
| EPS Growth Forecast (3Y) | 21.71% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | |
| Graham Formula Upside |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
AbbVie has an Altman Z-Score of 2.39 and a Piotroski F-Score of 7. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 2.39 |
| Piotroski F-Score | 7 |